Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Rocco

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Nature Biotechnology|July 9, 2015
The constrained prescription, interchangeability and substitution of biosimilarsPaola Minghetti, Paolo Rocco, Huub Schellekens
Journal of Forensic and Legal Medicine|February 25, 2018
Biosimilar switching and related medical liabilityPaolo Rocco, Sonia Selletti, Paola Minghetti
Drug Discovery Today|July 25, 2022
Medicinal products meet medical devices: Classification and nomenclature issues arising from their combined usePaolo Rocco, Umberto Maria Musazzi, Paola Minghetti
Applied Ergonomics|April 23, 2013
Acceptability of robotic manipulators in shared working environments through human-like redundancy resolutionAndrea Maria Zanchettin, Luca Bascetta, Paolo Rocco
Tumori|September 2, 2016
Risk management of in-hospital administration of anticancer drugs: impact of Raccomandazione 14 from the Italian Ministry of HealthAntonella Casiraghi, Silvia Franzè, Paolo Rocco, et al.
Drug Discovery Today|August 8, 2018
Copies of nonbiological complex drugs: generic, hybrid or biosimilar?Paolo Rocco, Umberto M Musazzi, Silvia Franzè, et al.
The Science of the Total Environment|September 25, 2018
The safety of tattoo inks: Possible options for a common regulatory frameworkPaola Minghetti, Umberto M Musazzi, Rossella Dorati, et al.
Journal of Clinical Medicine|December 24, 2021
Rituximab Therapy for Adults with Nephrotic Syndromes: Standard Schedules or B Cell-Targeted Therapy?Lucia Del Vecchio, Marco Allinovi, Paolo Rocco, et al.
International Journal of Pharmaceutics|July 2, 2023
Marketing authorisations for unmet medical needs: A critical appraisal of regulatory pathways in the European UnionSara Manellari, Umberto M Musazzi, Paolo Rocco, et al.
Drug Discovery Today|June 3, 2020
Old active ingredients in new medicinal products: is the regulatory path coherent with patients' expectations?Paola Minghetti, Umberto M Musazzi, Antonella Casiraghi, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Nature Biotechnology|July 9, 2015
The constrained prescription, interchangeability and substitution of biosimilarsPaola Minghetti, Paolo Rocco, Huub Schellekens
Journal of Forensic and Legal Medicine|February 25, 2018
Biosimilar switching and related medical liabilityPaolo Rocco, Sonia Selletti, Paola Minghetti
Drug Discovery Today|July 25, 2022
Medicinal products meet medical devices: Classification and nomenclature issues arising from their combined usePaolo Rocco, Umberto Maria Musazzi, Paola Minghetti
Applied Ergonomics|April 23, 2013
Acceptability of robotic manipulators in shared working environments through human-like redundancy resolutionAndrea Maria Zanchettin, Luca Bascetta, Paolo Rocco
Tumori|September 2, 2016
Risk management of in-hospital administration of anticancer drugs: impact of Raccomandazione 14 from the Italian Ministry of HealthAntonella Casiraghi, Silvia Franzè, Paolo Rocco, et al.
Drug Discovery Today|August 8, 2018
Copies of nonbiological complex drugs: generic, hybrid or biosimilar?Paolo Rocco, Umberto M Musazzi, Silvia Franzè, et al.
The Science of the Total Environment|September 25, 2018
The safety of tattoo inks: Possible options for a common regulatory frameworkPaola Minghetti, Umberto M Musazzi, Rossella Dorati, et al.
Journal of Clinical Medicine|December 24, 2021
Rituximab Therapy for Adults with Nephrotic Syndromes: Standard Schedules or B Cell-Targeted Therapy?Lucia Del Vecchio, Marco Allinovi, Paolo Rocco, et al.
International Journal of Pharmaceutics|July 2, 2023
Marketing authorisations for unmet medical needs: A critical appraisal of regulatory pathways in the European UnionSara Manellari, Umberto M Musazzi, Paolo Rocco, et al.
Drug Discovery Today|June 3, 2020
Old active ingredients in new medicinal products: is the regulatory path coherent with patients' expectations?Paola Minghetti, Umberto M Musazzi, Antonella Casiraghi, et al.
Pageof 3